Advertisement
Research Article Free access | 10.1172/JCI114242
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Find articles by Ahmad, S. in: JCI | PubMed | Google Scholar
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Find articles by Rawala-Sheikh, R. in: JCI | PubMed | Google Scholar
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Find articles by Ashby, B. in: JCI | PubMed | Google Scholar
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Find articles by Walsh, P. in: JCI | PubMed | Google Scholar
Published September 1, 1989 - More info
We have studied factor IXa binding and factor X activation with normal platelets and with platelets obtained from a patient with a bleeding disorder and an isolated deficiency of platelet procoagulant activity termed Scott syndrome. In the absence of factor VIIIa and factor X, normal, thrombin-treated platelets exposed 560 +/- 35 sites for factor IXa with a Kd of 2.75 +/- 0.27 mM, compared with 461 +/- 60 sites per patient platelet with Kd of 3.2 +/- 0.33 nM. The addition of factor VIIIa and factor X resulted in a decrease in the Kd for normal platelets to 0.68 nM but had no effect on the Kd for patient platelets. The concentrations of factor IXa required for half-maximal rates of factor X activation for normal (0.52 nM) and patient platelets (2.5 nM) were similar to those determined from equilibrium binding studies. Kinetic parameters for factor X activation by factor IXa showed that the Km and Kcat were identical for normal and patient platelets in the absence of factor VIIIa. In the presence of factor VIIIa, and kcat for patient platelets (163 min-1) was only 33% of that for normal platelets (491 min-1): This result can be explained by the difference in affinity for factor IXa between normal and patient platelets in the presence of factor VIIIa, suggesting impaired factor VIIIa binding to Scott syndrome platelets.